Current Therapeutic Options in Waldenström Macroglobulinemia
Open Access
- 1 January 2019
- journal article
- Published by Touch Medical Media, Ltd. in Oncology & Hematology Review
- Vol. 15 (1)
- https://doi.org/10.17925/ohr.2019.15.1.39
Abstract
No abstract availableFunding Information
- This article is published under the Creative Commons Attribution Non-commercial License.
This publication has 94 references indexed in Scilit:
- Acute hyperviscosity: syndromes and managementBlood, 2018
- Diagnosis and Management of Waldenström MacroglobulinemiaJAMA Oncology, 2017
- Prognostic factors and indications for treatment of Waldenström's MacroglobulinemiaBest Practice & Research Clinical Haematology, 2016
- Waldenstrom macroglobulinemia: prognosis and managementBlood Cancer Journal, 2015
- Progression in smoldering Waldenström macroglobulinemia: long-term resultsBlood, 2012
- Waldenström macroglobulinemiaHematology, 2012
- Evidence-based focused review of management of hyperviscosity syndromeBlood, 2012
- Waldenström macroglobulinemia: a Surveillance, Epidemiology, and End Results database review from 1988 to 2005Leukemia & Lymphoma, 2012
- Long-term survival in Waldenstrom macroglobulinemia: 10-year follow-up of Southwest Oncology Group–directed intergroup trial S9003Blood, 2009
- Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's MacroglobulinemiaSeminars in Oncology, 2003